Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

163 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4.
van den Bulk J, Verdegaal EME, Ruano D, Ijsselsteijn ME, Visser M, van der Breggen R, Duhen T, van der Ploeg M, de Vries NL, Oosting J, Peeters KCMJ, Weinberg AD, Farina-Sarasqueta A, van der Burg SH, de Miranda NFCC. van den Bulk J, et al. Among authors: van der burg sh, van der ploeg m, van der breggen r. Genome Med. 2019 Dec 30;11(1):87. doi: 10.1186/s13073-019-0697-8. Genome Med. 2019. PMID: 31888734 Free PMC article.
The identification of the anthracycline aclarubicin as an effective cytotoxic agent for pancreatic cancer.
Brouwer TP, van der Zanden SY, van der Ploeg M, van Eendenburg JDH, Bonsing BA, de Miranda NFCC, Neefjes JJ, Vahrmeijer AL. Brouwer TP, et al. Among authors: van eendenburg jdh, van der zanden sy, van der ploeg m. Anticancer Drugs. 2022 Aug 1;33(7):614-621. doi: 10.1097/CAD.0000000000001283. Epub 2022 Mar 23. Anticancer Drugs. 2022. PMID: 35324522 Free PMC article.
γδ T cells are effectors of immunotherapy in cancers with HLA class I defects.
de Vries NL, van de Haar J, Veninga V, Chalabi M, Ijsselsteijn ME, van der Ploeg M, van den Bulk J, Ruano D, van den Berg JG, Haanen JB, Zeverijn LJ, Geurts BS, de Wit GF, Battaglia TW, Gelderblom H, Verheul HMW, Schumacher TN, Wessels LFA, Koning F, de Miranda NFCC, Voest EE. de Vries NL, et al. Among authors: van der ploeg m. Nature. 2023 Jan;613(7945):743-750. doi: 10.1038/s41586-022-05593-1. Epub 2023 Jan 11. Nature. 2023. PMID: 36631610 Free PMC article.
CD103 and CD39 coexpression identifies neoantigen-specific cytotoxic T cells in colorectal cancers with low mutation burden.
van den Bulk J, van der Ploeg M, Ijsselsteijn ME, Ruano D, van der Breggen R, Duhen R, Peeters KCMJ, Fariña-Sarasqueta A, Verdegaal EME, van der Burg SH, Duhen T, de Miranda NFCC. van den Bulk J, et al. Among authors: van der ploeg m. J Immunother Cancer. 2023 Feb;11(2):e005887. doi: 10.1136/jitc-2022-005887. J Immunother Cancer. 2023. PMID: 36792124 Free PMC article.
Neoantigen Targetability in Progressive Advanced Melanoma.
van den Bulk J, Verdegaal EME, van der Ploeg M, Visser M, Nunes JB, de Ru AH, Tjokrodirijo RTN, Ijsselsteijn ME, Janssen NI, van der Breggen R, de Bruin L, de Kok P, Janssen GMC, Ruano D, Kapiteijn EHW, van Veelen PA, de Miranda NFCC, van der Burg SH. van den Bulk J, et al. Among authors: van der ploeg m. Clin Cancer Res. 2023 Oct 13;29(20):4278-4288. doi: 10.1158/1078-0432.CCR-23-1106. Clin Cancer Res. 2023. PMID: 37540567 Free PMC article.
Multimodal profiling of chordoma immunity reveals distinct immune contextures.
van Oost S, Meijer DM, Ijsselsteijn ME, Roelands JP, van den Akker BEMW, van der Breggen R, Briaire-de Bruijn IH, van der Ploeg M, Wijers-Koster PM, Polak SB, Peul WC, van der Wal RJP, de Miranda NFCC, Bovee JVMG. van Oost S, et al. Among authors: van der ploeg m. J Immunother Cancer. 2024 Jan 25;12(1):e008138. doi: 10.1136/jitc-2023-008138. J Immunother Cancer. 2024. PMID: 38272563 Free PMC article.
163 results